분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2018-08-19 18:57:50 , Hit : 270
 Lenvima OK'd as First-Line Treatment for Unresectable Hepatocellular Carcinoma

https://www.empr.com/news/lenvima-lenvatinib-hepatocellular-carcinoma-approved-hcc-liver-cancer/article/789154/


MPR >
News >
Lenvima OK'd as First-Line Treatment for Unresectable Hepatocellular Carcinoma

  


Da Hee Han, PharmD


August 16, 2018

The Food and Drug Administration (FDA) has approved Lenvima (lenvatinib; Eisai) as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC).

The approval was supported by findings from the multicenter, randomized, open-label, noninferiority trial, REFLECT (N=945), which included patients with previously untreated, metastatic or unresectable HCC. Study patients received Lenvima based on actual body weight or sorafenib until radiological disease progression or unacceptable toxicity.

Lenvima proved noninferior but not statistically superior to sorafenib for overall survival (hazard ratio [HR] 0.92, 95% CI, 0.79, 1.06). In the Lenvima arm, median overall survival was 13.6 months compared with 12.3 months in the sorafenib arm. Also, a statistically significant improvement in progression-free survival (PFS) was seen with Lenvima vs sorafenib (7.3 months vs 3.6 months; HR 0.64, 95% CI, 0.55, 0.75; P <.001) according to modified Response Evaluation Criteria in Solid Tumors (RECIST) for HCC. Moreover, the objective response rate was greater in the Lenvima arm compared with sorafenib (41% vs 12% per mRECIST; 19% vs 7% per RECIST 1.1).  



Related Articles
Keytruda sBLA Granted Priority Review for Advanced Hepatocellular Carcinoma
Positive Top-Line Results for Ramucirumab in HCC Announced
BMI Linked to Hepatocellular Carcinoma Risk in Chronic Hep B


Lenvima, a kinase inhibitor, is already indicated in combination with everolimus to treat advanced renal cell carcinoma, following one prior anti-angiogenic therapy; and to treat locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.

It is supplied as 4mg and 10mg strength capsules.

For more information call (877) 873-4724 or visit Lenvima.com.







1267   [바이오토픽] CRISPR 특허전쟁 항소심, 브로드 연구소 승리  이성욱 2018/09/11 246
1266   Lethal Viruses Hijack DNA-Damage Response, May Be Exploited for Cancer  이성욱 2018/08/07 261
1265   Ruling on gene editing crops a threat to innovation and future food security, scientists say  이성욱 2018/07/28 265
  Lenvima OK'd as First-Line Treatment for Unresectable Hepatocellular Carcinoma  이성욱 2018/08/19 270
1263   CRISPR-Cas12a More Precise Than CRISPR-Cas9  이성욱 2018/08/07 284
1262   Doubts arise again about CRISR'd human embryos  이성욱 2018/08/09 288
1261   RNA World May Have Started Spinning with Triplet-Based Synthesis  이성욱 2018/05/21 295
1260   [바이오토픽] 유전자를 침묵시키는 신약, 20년의 기다림 끝에 승인  이성욱 2018/08/13 298
1259   Another "CRISPR Calamity"? U.K. Team Reports CRISPR-Induced Gene Rearrangements  이성욱 2018/07/17 299
1258   Gene Therapy Ever More Common for Rare Disorders  이성욱 2018/05/30 332
1257   CRISPR Efficiency Tied to Cancer-Causing Process  이성욱 2018/06/13 332
1256   Frances H. Arnold, George P. Smith, and Gregory P. Winter share 2018 Nobel Prize in Chemistry  이성욱 2018/10/04 349
1255   RNA-Based Gene Therapy Can Be Turned ON or OFF via Synbio Switches  이성욱 2018/10/18 354
1254   Cause of CRISPR Failure Identified and Reversed  이성욱 2018/07/12 355
1253   Keytruda Gets FDA Approval for Hepatocellular Carcinoma  이성욱 2018/11/14 355
1252   Novel Two-Pronged Method Targets Cancer Cells’ Telomerase and Chromosomes  이성욱 2018/11/03 365
1251   Immunotherapy Pioneers Take 2018 Nobel Prize  이성욱 2018/10/02 370
1250   Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness  이성욱 2017/12/20 371
1249   Checkpoint Inhibitor Generated by Synthetic DNA in Vivo  이성욱 2018/10/06 376
1248   분자수준 인체 간세포 지도 처음 작성  이성욱 2018/10/24 380

1 [2][3][4][5][6][7][8][9][10]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN